Drugs / Exenatide LAR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00103935 | Feb → Oct 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02811484 | Jun 2016 → Jun 2018 | type 2 diabetes mellitus | Weill Medical College of Cornell University | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03444142 Comparator | Nov 2017 → Nov 2021 | type 2 diabetes mellitus | University of Guadalajara | Unknown | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2006-06-12 | Eli Lilly and Company | Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes lilly.com ↗ |
| 2006-06-10 | Eli Lilly and Company | Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes lilly.com ↗ |
| 2006-03-24 | Eli Lilly and Company | Once-Weekly Exenatide LAR Clinical Study in Type 2 Diabetes Initiated lilly.com ↗ |
| 2005-08-22 | Eli Lilly and Company | Once Weekly Exenatide LAR Well Tolerated and Improved Glucose Control lilly.com ↗ |
| 2005-08-22 | Eli Lilly and Company | Once Weekly Exenatide LAR Well Tolerated and Improved Glucose Control; Preliminary Results From Phase 2 Study Announced lilly.com ↗ |
| 2004-11-02 | Eli Lilly and Company | Exenatide LAR Data Support Initiation of Phase 2 Multi-Dose Study in 2005 lilly.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exenatide LAR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00103935 ↗ |
| Route | Subcutaneous | “Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.” NCT00103935 ↗ |